Literature DB >> 24844303

Therapeutic potential of STAT4 in autoimmunity.

Yan Liang1, Hai-Feng Pan, Dong-Qing Ye.   

Abstract

INTRODUCTION: STAT4, which acts as the major signaling transducing STATs in response to IL-12, is a central mediator in generating inflammation during protective immune responses and immune-mediated diseases. AREAS COVERED: This review summarizes that STAT4 is essential for the differentiation and function of a wide variety of immune cells, including natural killer cells, mast cells, dendritic cells and T helper cells. In addition, STAT4-mediated signaling promoted the production of autoimmune-associated components, which are implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and psoriasis. EXPERT OPINION: Due to its crucial roles in inflammation and autoimmunity, STAT4 may have promise as an effective therapeutic target for autoimmune diseases. Understanding the molecular mechanisms driving STAT4, together with knowledge on the ability of current immunosuppressive treatment to target this process, may open an avenue to novel therapeutic options.

Entities:  

Keywords:  autoimmune diseases; cytokine signaling; immune cells; signaling transducers and activators of transcription 4

Mesh:

Substances:

Year:  2014        PMID: 24844303     DOI: 10.1517/14728222.2014.920325

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

Review 1.  Genetics of autoimmune diseases: perspectives from genome-wide association studies.

Authors:  Yuta Kochi
Journal:  Int Immunol       Date:  2016-02-08       Impact factor: 4.823

Review 2.  Genetics of systemic sclerosis.

Authors:  Lara Bossini-Castillo; Elena López-Isac; Maureen D Mayes; Javier Martín
Journal:  Semin Immunopathol       Date:  2015-06-02       Impact factor: 9.623

Review 3.  Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Authors:  Mohammed M Al Gadban; Mohamed M Alwan; Kent J Smith; Samar M Hammad
Journal:  Clin Immunol       Date:  2015-01-28       Impact factor: 3.969

4.  An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.

Authors:  L Zhao; G Ji; X Le; Z Luo; C Wang; M Feng; L Xu; Y Zhang; W B Lau; B Lau; Y Yang; L Lei; H Yang; Y Xuan; Y Chen; X Deng; T Yi; S Yao; X Zhao; Y Wei; S Zhou
Journal:  Oncogene       Date:  2017-01-23       Impact factor: 9.867

Review 5.  Genetics of systemic sclerosis.

Authors:  Yuki Ishikawa; Chikashi Terao
Journal:  J Scleroderma Relat Disord       Date:  2020-04-19

6.  STAT4 Polymorphisms are Associated with Neuromyelitis Optica Spectrum Disorders.

Authors:  Ziyan Shi; Qin Zhang; Hongxi Chen; Zhiyun Lian; Ju Liu; Huiru Feng; Xiaohui Miao; Qin Du; Hongyu Zhou
Journal:  Neuromolecular Med       Date:  2017-08-29       Impact factor: 3.843

7.  Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice.

Authors:  Elżbieta Wyska; Artur Świerczek; Krzysztof Pociecha; Katarzyna Przejczowska-Pomierny
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-08       Impact factor: 2.441

8.  Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis.

Authors:  Dandan Fu; Xiangfeng Song; Hua Hu; Min Sun; Zhanguo Li; Zhongwei Tian
Journal:  Mol Med Rep       Date:  2016-04-12       Impact factor: 2.952

9.  Contribution of the STAT4 rs7574865 gene polymorphism to the susceptibility to autoimmune thyroiditis in healthy Turk population and psoriatic subgroups.

Authors:  Meliha M Hiz; Sevilay Kılıç; Selda Işık; Zerrin Ogretmen; Fatma Silan
Journal:  Cent Eur J Immunol       Date:  2016-01-15       Impact factor: 2.085

10.  The Four-Way Stop Sign: Viruses, 12-Lipoxygenase, Islets, and Natural Killer Cells in Type 1 Diabetes Progression.

Authors:  Michele L Semeraro; Lindsey M Glenn; Margaret A Morris
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.